Showing results (201-210 of 240) with videos related to
Sort By:
Pageof 24
BJU International|November 9, 2000
Computed tomography 21 days after chemotherapy, three-dimensional estimates of metastatic volume and the need for surgery in patients with germ cell cancerH S Bozcuk, R Ravi, B Turner, et al.Current Medical Research and Opinion|May 27, 2017
A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapyR Ravi Shankar, Silvio E Inzucchi, Victoria Scarabello, et al.Tropical Biomedicine|January 31, 2026
Molecular surveillance of insecticide resistance: High frequency of kdr mutations in permethrin-exposed Aedes mosquitoes from Kuala Lumpur and Selangor, MalaysiaN S N Saiful Anuar, F Izzat, Z Rahman, et al.Novartis Foundation Symposium|December 1, 2001
'The metabolism of tumours': 70 years laterG L Semenza, D Artemov, A Bedi, et al.Pediatric Diabetes|May 16, 2018
Changes in diabetes medication regimens and glycemic control in adolescents and young adults with youth-onset type 2 diabetes: The SEARCH for diabetes in youth studyCathy A Pinto, Jeanette M Stafford, Tongtong Wang, et al.Diabetes, Obesity & Metabolism|September 5, 2018
Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulinMiao Yu, R Ravi Shankar, Ruya Zhang, et al.Journal of Diabetes|August 10, 2016
Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metforminJianming Ba, Ping Han, Guoyue Yuan, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 31, 2015
A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin GlargineChantal Mathieu, R Ravi Shankar, Daniel Lorber, et al.Genes & Development|January 20, 2000
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alphaR Ravi, B Mookerjee, Z M Bhujwalla, et al.Bioorganic & Medicinal Chemistry|April 10, 2007
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2Allan Wissner, Heidi L Fraser, Charles L Ingalls, et al.Pageof 24